The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Signs of an inflammatory process, in particular increased pro-inflammatory cytokines and increased levels of prostaglandine E(2) (PGE(2)), have repeatedly been described in major depression (MD). As cyclooxygenase-2 (COX-2) inhibitors inhibit the PGE(2) production and the production of pro-inflammatory cytokines, we performed a therapeutic trial with the COX-2 inhibitor celecoxib. In a prospective, double-blind, add-on study, 40 patients suffering from an acute depressive episode were randomly assigned to either reboxetine and celecoxib or to reboxetine plus placebo. After a wash-out period, 20 patients received 4-10 mg reboxetine plus placebo and 20 received reboxetine plus 400 mg celecoxib for 6 weeks. The treatment effect was calculated by analysis of variance. There were no significant differences between groups in age, sex, duration or severity of disease or psychopathology, or reboxetine dose or plasma levels. Over 6 weeks, both groups of patients showed significant improvement in scores of the Hamilton Depression Scale. However, the celecoxib group showed significantly greater improvement compared to the reboxetine-alone group. Additional treatment with celecoxib has significant positive effects on the therapeutic action of reboxetine with regard to depressive symptomatology. Moreover, the fact that treatment with an anti-inflammatory drug showed beneficial effects on MD indicates that inflammation is related to the pathomechanism of the disorder, although the exact mechanisms remain to become elucidated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients in the reboxetine plus celecoxib group exhibited reductions in depression severity that were nearly twice as great (55% reduction) as those experienced by patients in the control group (33% reduction).”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“75% of patients receiving reboxetine plus celecoxib were categorized as responders, compared to only 45% of patients receiving reboxetine plus placebo”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“TNFα antagonists such as etanercept or infliximab and the COX-2 inhibitor celecoxib have all been found to alleviate depressive symptoms in double-blind, randomized, placebo-controlled studies”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“One study found positive effects on mood in medically healthy, major depressed patients.52”
From Association of depressive disorders, depression characteristics and antidepressant medication with inflammation (2012) · cites this paper as [52]
In the citing paper
“from the administration of COX2 inhibitors to patients with major depression81”
From From inflammation to sickness and depression: when the immune system subjugates the brain (2008) · cites this paper as [81]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The global burden of disease, 1990–2020
Lopez, A. D., & Murray, C. C. J. L. (1998) · Nature Medicine · doi:10.1038/3218 · Cited by 1,614
Cytokine-induced sickness behavior: where do we stand?
Dantzer, R. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0613 · Cited by 862
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735
Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., & Neels, H. (1997) · Cytokine · doi:10.1006/cyto.1997.0238 · Cited by 728
Maes, M., Scharpé, S., Meltzer, H. Y., Bosmans, E., Suy, E., Calabrese, J., & Cosyns, P. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90027-e · Cited by 439
Müller, N., Riedel, M., Scheppach, C., Brandstätter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R. R., Möller, H.-J., & Schwarz, M. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1029 · Cited by 388
Self-citationFrommberger, U. H., Bauer, J., Haselbauer, P., Fräulin, A., Riemann, D., & Berger, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02900219 · Cited by 362
Capuron, L., Ravaud, A., Miller, A. H., & Dantzer, R. (2004) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2003.11.004 · Cited by 236
Song, C., Lin, A., Bonaccorso, S., Heide, C., Verkerk, R., Kenis, G., Bosmans, E., Scharpe, S., Whelan, A., Cosyns, P., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00025-1 · Cited by 232
Hajós, M., Fleishaker, J. C., Filipiak‐Reisner, J. K., Brown, M. T., & Wong, E. H. F. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00002.x · Cited by 218
Reboxetine: the first selective noradrenaline re-uptake inhibitor
Kasper, S., Giamal, N. E., & Hilger, E. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.4.771 · Cited by 210
Depression, immunocompetence, and prostaglandins of the E series
Calabrese, J. R., Skwerer, R. G., Barna, B., Gulledge, A. D., Valenzuela, R., Butkus, A., Subichin, S., & Krupp, N. E. (1986) · Psychiatry Research · doi:10.1016/0165-1781(86)90040-5 · Cited by 205
Low levels of circulating inflammatory cytokines—Do they affect human brain functions?
Pollmächer, T., Haack, M., Schuld, A., Reichenberg, A., & Yirmiya, R. (2002) · Brain, Behavior, and Immunity · doi:10.1016/s0889-1591(02)00004-1 · Cited by 202
Casolini, P., Catalani, A., Zuena, A. R., & Angelucci, L. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10192 · Cited by 174
Inflammatory markers in major depression and melancholia.
Rothermundt, M., Arolt, V., Peters, M., Gutbrodt, H., Fenker, J., Kersting, A., & Kirchner, H. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00157-9 · Cited by 174
Self-citationCSF Prostaglandin Levels in Depressed and Schizophrenic Patients
Linnoila, M. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790040059008 · Cited by 150
Increased level of salivary prostaglandins in patients with major depression
Ohishi, K., Ueno, R., Nishino, S., Sakai, T., & Hayaishi, O. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90283-1 · Cited by 138
Clinical effects of COX?2 inhibitors on cognition in schizophrenia
M�ller, N., Riedel, M. J., Schwarz, M., & Engel, R. R. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0548-4 · Cited by 135
Self-citationMüller, N., Hofschuster, E., Ackenheil, M., Mempel, W., & Eckstein, R. (1993) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(93)90055-w · Cited by 106
Self-citationCao, C., Matsumura, K., Ozaki, M., & Watanabe, Y. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-02-00716.1999 · Cited by 105
Salivary prostaglandin concentrations: possible state indicators for major depression
Nishino, S., Ueno, R., Ohishi, K., Sakai, T., & Hayaishi, O. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.3.365 · Cited by 88
West, D. V., & Maes, M. H. J. (1999) · PubMed · Cited by 84
Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function
Hu, F., Wang, X., Pace, T. W. W., Wu, H., & Miller, A. H. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001644 · Cited by 76
Effect of rofecoxib on nociception and the serotonin system in the rat brain
Sandrini, M., Vitale, G., & Pini, L. A. (2002) · Inflammation Research · doi:10.1007/pl00000287 · Cited by 75
Schaefer, M., Horn, M., Schmidt, F., Schmid-Wendtner, M.-H., Volkenandt, M., Ackenheil, M., Mueller, N., & Schwarz, M. (2004) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2004.02.002 · Cited by 75
Self-citationMultiple sclerosis and depression: influence of interferon b therapy
Zéphir, H., Seze, J. D., Stojkovic, T., Delisse, B., Ferriby, D., Cabaret, M., & Vermersch, P. (2003) · Multiple Sclerosis Journal · doi:10.1191/1352458503ms915oa · Cited by 75
Collantes‐Estévez, E., & Fernández, C. (2003) · Current Medical Research and Opinion · doi:10.1185/030079903125001938 · Cited by 52
Yirmiya, R., Barak, O., Avitsur, R., Gallily, R., & Weidenfeld, J. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01295-4 · Cited by 45
Fundamentals of Psychoneuroimmunology
Song, C., & Leonard, B. E. (2000) · Cited by 43
Fundamentals of Psychoneuroimmunology
Pariante, C. M. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01333.x · Cited by 43
Fundamentals of Psychoneuroimmunology
Pariante, C. M. (2001) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2001.01333.x · Cited by 43
COX-2 inhibitors as adjunctive therapy in schizophrenia
Müller, N., Strassnig, M., Schwarz, M., Ulmschneider, M., & Riedel, M. J. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.8.1033 · Cited by 42
Self-citationMtabaji, J., Manku, M. S., & Horrobin, D. F. (1977) · Prostaglandins · doi:10.1016/0090-6980(77)90161-7 · Cited by 36
Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus
Ferro, D., Basili, S., Roccaforte, S., Franco, M. D., Cipollone, F., Ciabattoni, G., & Dav�, G. (1999) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199912)42:12<2561::aid-anr8>3.0.co;2-u · Cited by 36
Beyond the Kraepelinean Dichotomy
Wexler, B. E. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90240-z · Cited by 28
Nishino, S. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.12.1647 · Cited by 19
Lactate sensitivity in sleeping panic disorder patients and healthy controls
Koenigsberg, H. W., Pollak, C. P., Fine, J., & Kakuma, T. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90222-l · Cited by 12
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848
Slavich, G. M., & Irwin, M. R. (2014) · Psychological Bulletin · doi:10.1037/a0035302 · Cited by 2,206
“Moreover, 75% of patients receiving reboxetine plus celecoxib were categorized as responders, compared to only 45% of patients receiving reboxetine plus placebo (Müller et al., 2006; see also Akhondzadeh et al., 2009).”
MethodResult
Metadata
- Authors
- Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., Möller, H.-J., Arolt, V, & Riedel, M.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- University of Münster (DE)
- Corresponding author
- Müller, N
- Venue
- Molecular Psychiatry
- Published
- 2006-02-21
- Volume
- 11
- Issue
- 7
- Pages
- 680-684
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2049808835
- Cited by
- 794
- References
- 37
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 24 · 2023: 30 · 2022: 42 · 2021: 42 · 2020: 37 · 2019: 44 · 2018: 52 · 2017: 45 · 2016: 42 · 2015: 54 · 2014: 53 · 2013: 61 · 2012: 50
- FWCI
- 20.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- celecoxib, COX-2 inhibitors, major depressive disorder, reboxetine, anti-inflammatory therapy, inflammatory cytokines, prostaglandin E2, adjunctive therapy, acute depressive episode
- MeSH terms
- Celecoxib, Reboxetine, Adult, Antidepressive Agents, Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Inflammation, Lorazepam, Male, Middle Aged, Morpholines, Patient Dropouts, Pilot Projects, Psychological Tests, Pyrazoles, Serotonin, Severity of Illness Index, Sulfonamides, Anti-Anxiety Agents, Dinoprostone, Interleukin-6, Adrenergic Uptake Inhibitors, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.